Cargando…
Suboptimal primary and secondary cardiovascular disease prevention in HIV-positive individuals on antiretroviral therapy
BACKGROUND: We aimed to identify the prevalence of cardiovascular risk factors, and investigate preventive cardiovascular medication use and achievement of targets as per Dutch cardiovascular risk management guidelines among human immunodeficiency virus (HIV)-positive and HIV-negative individuals. D...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548068/ https://www.ncbi.nlm.nih.gov/pubmed/28578613 http://dx.doi.org/10.1177/2047487317714350 |
_version_ | 1783255785121251328 |
---|---|
author | van Zoest, Rosan A van der Valk, Marc Wit, Ferdinand W Vaartjes, Ilonca Kooij, Katherine W Hovius, Joppe W Prins, Maria Reiss, Peter |
author_facet | van Zoest, Rosan A van der Valk, Marc Wit, Ferdinand W Vaartjes, Ilonca Kooij, Katherine W Hovius, Joppe W Prins, Maria Reiss, Peter |
author_sort | van Zoest, Rosan A |
collection | PubMed |
description | BACKGROUND: We aimed to identify the prevalence of cardiovascular risk factors, and investigate preventive cardiovascular medication use and achievement of targets as per Dutch cardiovascular risk management guidelines among human immunodeficiency virus (HIV)-positive and HIV-negative individuals. DESIGN: The design was a cross-sectional analysis within an ongoing cohort study. METHODS: Data on medication use and cardiovascular disease prevalence were available for 528 HIV-positive and 521 HIV-negative participants. We identified cardiovascular risk factors and applied cardiovascular risk management guidelines, mainly focusing on individuals eligible for (a) primary prevention because of high a priori cardiovascular risk, or for (b) secondary prevention. RESULTS: One hundred and three (20%) HIV-positive and 77 (15%) HIV-negative participants were classified as having high cardiovascular risk; 53 (10%) HIV-positive and 27 (5%) HIV-negative participants were eligible for secondary prevention. Of HIV-positive individuals 57% at high cardiovascular risk and 42% of HIV-positive individuals eligible for secondary prevention had systolic blood pressures above guideline-recommended thresholds. Cholesterol levels were above guideline-recommended thresholds in 81% of HIV-positive individuals at high cardiovascular risk and 57% of HIV-positive individuals eligible for secondary prevention. No statistically significant differences were observed between HIV-positive and HIV-negative participants regarding achievement of targets, except for glycaemic control (glycated haemoglobin ≤ 53 mmol/mol) among individuals using diabetes medication (90% vs 50%, p = 0.017) and antiplatelet/anticoagulant use for secondary prevention (85% vs 63%, p = 0.045), which were both superior among HIV-positive participants. CONCLUSIONS: Cardiovascular risk management is suboptimal in both HIV-positive and HIV-negative individuals and should be improved. |
format | Online Article Text |
id | pubmed-5548068 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-55480682017-08-23 Suboptimal primary and secondary cardiovascular disease prevention in HIV-positive individuals on antiretroviral therapy van Zoest, Rosan A van der Valk, Marc Wit, Ferdinand W Vaartjes, Ilonca Kooij, Katherine W Hovius, Joppe W Prins, Maria Reiss, Peter Eur J Prev Cardiol CVD Risk Factors BACKGROUND: We aimed to identify the prevalence of cardiovascular risk factors, and investigate preventive cardiovascular medication use and achievement of targets as per Dutch cardiovascular risk management guidelines among human immunodeficiency virus (HIV)-positive and HIV-negative individuals. DESIGN: The design was a cross-sectional analysis within an ongoing cohort study. METHODS: Data on medication use and cardiovascular disease prevalence were available for 528 HIV-positive and 521 HIV-negative participants. We identified cardiovascular risk factors and applied cardiovascular risk management guidelines, mainly focusing on individuals eligible for (a) primary prevention because of high a priori cardiovascular risk, or for (b) secondary prevention. RESULTS: One hundred and three (20%) HIV-positive and 77 (15%) HIV-negative participants were classified as having high cardiovascular risk; 53 (10%) HIV-positive and 27 (5%) HIV-negative participants were eligible for secondary prevention. Of HIV-positive individuals 57% at high cardiovascular risk and 42% of HIV-positive individuals eligible for secondary prevention had systolic blood pressures above guideline-recommended thresholds. Cholesterol levels were above guideline-recommended thresholds in 81% of HIV-positive individuals at high cardiovascular risk and 57% of HIV-positive individuals eligible for secondary prevention. No statistically significant differences were observed between HIV-positive and HIV-negative participants regarding achievement of targets, except for glycaemic control (glycated haemoglobin ≤ 53 mmol/mol) among individuals using diabetes medication (90% vs 50%, p = 0.017) and antiplatelet/anticoagulant use for secondary prevention (85% vs 63%, p = 0.045), which were both superior among HIV-positive participants. CONCLUSIONS: Cardiovascular risk management is suboptimal in both HIV-positive and HIV-negative individuals and should be improved. SAGE Publications 2017-06-05 2017-08 /pmc/articles/PMC5548068/ /pubmed/28578613 http://dx.doi.org/10.1177/2047487317714350 Text en © The European Society of Cardiology 2017 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | CVD Risk Factors van Zoest, Rosan A van der Valk, Marc Wit, Ferdinand W Vaartjes, Ilonca Kooij, Katherine W Hovius, Joppe W Prins, Maria Reiss, Peter Suboptimal primary and secondary cardiovascular disease prevention in HIV-positive individuals on antiretroviral therapy |
title | Suboptimal primary and secondary cardiovascular disease prevention in HIV-positive individuals on antiretroviral therapy |
title_full | Suboptimal primary and secondary cardiovascular disease prevention in HIV-positive individuals on antiretroviral therapy |
title_fullStr | Suboptimal primary and secondary cardiovascular disease prevention in HIV-positive individuals on antiretroviral therapy |
title_full_unstemmed | Suboptimal primary and secondary cardiovascular disease prevention in HIV-positive individuals on antiretroviral therapy |
title_short | Suboptimal primary and secondary cardiovascular disease prevention in HIV-positive individuals on antiretroviral therapy |
title_sort | suboptimal primary and secondary cardiovascular disease prevention in hiv-positive individuals on antiretroviral therapy |
topic | CVD Risk Factors |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548068/ https://www.ncbi.nlm.nih.gov/pubmed/28578613 http://dx.doi.org/10.1177/2047487317714350 |
work_keys_str_mv | AT vanzoestrosana suboptimalprimaryandsecondarycardiovasculardiseasepreventioninhivpositiveindividualsonantiretroviraltherapy AT vandervalkmarc suboptimalprimaryandsecondarycardiovasculardiseasepreventioninhivpositiveindividualsonantiretroviraltherapy AT witferdinandw suboptimalprimaryandsecondarycardiovasculardiseasepreventioninhivpositiveindividualsonantiretroviraltherapy AT vaartjesilonca suboptimalprimaryandsecondarycardiovasculardiseasepreventioninhivpositiveindividualsonantiretroviraltherapy AT kooijkatherinew suboptimalprimaryandsecondarycardiovasculardiseasepreventioninhivpositiveindividualsonantiretroviraltherapy AT hoviusjoppew suboptimalprimaryandsecondarycardiovasculardiseasepreventioninhivpositiveindividualsonantiretroviraltherapy AT prinsmaria suboptimalprimaryandsecondarycardiovasculardiseasepreventioninhivpositiveindividualsonantiretroviraltherapy AT reisspeter suboptimalprimaryandsecondarycardiovasculardiseasepreventioninhivpositiveindividualsonantiretroviraltherapy |